Dr. WU Yusheng obtained his doctor’s degree in organic chemistry from Iowa State University of Science and Technology. Dr. Wu has more than 25 years of experience in biomedical research and management. He worked at Schering-Plough Corporation, an American pharmaceutical company principally engaged in new drug development as senior principal scientist, where he was primarily responsible for novel drug discovery such as for thrombosis, obesity and Alzheimer’s disease. Dr. Wu obtained various awards during his professional career, including the New Jersey Minority Award from the Plainfield and Metuchen-Edison YMCA in 2004, and the 2006 President’s Award for Discovery from Schering-Plough Research Institute. Further, Dr. Wu has been a “State Specially Recruited Expert” as conferred by the Ministry of Human Resources and Social Security of the PRC since 2013. Dr. Wu has also authored more than 120 scientific publications in leading chemistry and medicinal chemistry journals and has been granted more than 40 granted patents.

Dr. LI Jun obtained his doctor’s degree in organic chemistry from Iowa State University of Science and Technology. He has over 20 years of experience in pharmaceutical research and investments. Dr. Li was a research scientist and group leader at the Institute of Materia Medica, Chinese Academy of Medical Sciences, where he was involved in setting up the PRC’s first doping control laboratory accredited by the International Olympic Committee. He worked for over 20 years as a principal scientist and program leader at Bristol-Myers Squibb Co., USA, where he was primarily responsible for new drug discovery. Dr. Li co-authored over 50 peer-reviewed research papers and has been granted more than 50 U.S. or Patent Cooperation Treaty (PCT) patents. Dr. Li obtained various awards during his professional career, including the PRC “First Prize of the State Scientific and Technological Progress Award” from the national government of the PRC, the “Special Prize” of the China Association for Instrumental Analysis (CAIA), along with two “Molecule of the Year” awards and a “Chemistry Leadership Award” from Bristol Myers Squibb Co., USA.

Dr.GU Eric Hong obtained his doctor’s degree in chemistry from the University of Missouri-St. Louis in Missouri. He has extensive experience in the pharmaceutical industry. He worked at Mallinckrodt Pharmaceuticals plc (formerly known as Mallinckrodt Inc.), a company engaged in R&D of drugs for autoimmune diseases and other diseases. Since July 2017, he has been certified as a professor-level senior engineer in drug development by the Zhejiang Provincial Department of Human Resources and Social Security.

Dr. JIANG Mingyu obtained his doctor’s degree in pharmacoeconomics at China Pharmaceutical University. He has more than 10 years of experience in auditing, risk management, and equity research. He worked at KPMG Huazhen LLP, KPMG Advisory (China) Co., Ltd., Shanghai Pudong Science & Technology Investment Co., Ltd., and Zheshang Securities Co., Ltd. (stock code: 601878). He independently led the company’s investment and financing business, accumulating tens of billions of yuan in financing for new drug companies, and independently led multiple new drug M&A and license-out projects of the company. Dr. Jiang has been certified as a financial risk manager by the Global Association of Risk Professionals since September 2012.

Dr. MENG Xiaoying obtained her doctor’s degree in plant biology from the Pennsylvania State University. She has extensive experience in investment and management, mainly focusing on biotechnology, pharmaceutical technology, medical services, and other related areas, having led and participated in over 30 investment projects. she was a director at BMC Medical Co., Ltd., a medical devices company listed on the Shenzhen Stock Exchange (stock code: 301367).

Mr. HE Chao obtained his master’s degree in business administration from Peking University. He has more than 10 years of experience in investment and finance. He successively served as a business director, branch general manager, and partner of Kunwu Jiuding Investment Management Co., Ltd., an equity investment company. He has been working at Beijing Huge Capital Management Co., Ltd., an equity investment company, as the general manager since July 2015 and as an executive director since February 2017.

Dr. Zhu Xiangyang obtained a Ph.D. degree in immunology from University of Illinois. He has over 20 years of experience in the biopharmaceutical industry. He currently serves as a consultant to the Company. He conducted postdoctoral research at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Dr. Zhu has worked in different fields and locations at Boehringer Ingelheim (BI), and possesses rich R&D and management experience in multinational pharmaceutical companies. He is currently a Director and General Manager of Shanghai Huaaotech Biopharmaceutical Co., Ltd. and a Director of Zhejiang Huahai Biotechnology Co., Ltd.

Mr. ZHANG Senquan obtained a bachelor’s degree in investment economics from Fudan University. Mr. Zhang has been admitted as a member of the Chinese Institute of Certified Public Accountants since December 2001, as a member of the Hong Kong Institute of Certified Public Accountants since September 2011 and further admitted as a member of the American Institute of Certified Public Accountants since September 2015.He has over 20 years of experience in accounting, auditing, and management. He has served as an independent non-executive director for multiple listed companies, including Beijing Digital Telecom Co., Ltd. (stock code: 6188), Bonny International Holding Limited (stock code: 1906), Jiangsu Aidea Pharmaceutical Co., Ltd. (stock code: 688488), Sang Hing Holdings (International) Ltd. (stock code: 1472), and others.

Dr. LENG Yuting obtained her doctor’s degree in organic chemistry from Zhengzhou University. She has more than 10 years of experience in organic chemistry research and management. She was a visiting scholar at Harvard Medical School and the Massachusetts General Hospital under the Visiting Scholar Program of the China Scholarship Council. Since December 2016, she was appointed as a postdoctoral researcher in medicinal chemistry at Zhengzhou University. Since January 2024, Dr. Leng has served as an associate professor at the College of Chemistry at Zhengzhou University, and has been long engaged in teaching and scientific research work.

Dr. XU Wenqing obtained his doctor’s degree in biology from the Massachusetts Institute of Technology in Massachusetts. He has over 15 years of experience in teaching and academia. Dr. Xu received the Investigator’s Award in the pathogenesis of infectious disease from the Burroughs Wellcome Fund in 2003.He has served as a tenured full professor at the University of Washington School of Medicine, and as Director of the National Facility for Protein Science in Shanghai. Since August 2019, he has been a tenured full professor at Shanghai Tech University

Dr. SHEN Xiuhua obtained her doctor’s degree in pediatrics from Shanghai Jiao Tong University. Dr. Shen has a wealth of experience in teaching and academia. She was a visiting scholar at the Division of Nutritional Sciences, Cornell University, and at Harvard University. Since August 1995, Dr. Shen consecutively worked as a teaching assistant in the Department of Pathology of the School of Medicine, a lecturer, an associate professor and currently a professor in the Department of Nutrition of the School of Medicine at Shanghai Jiao Tong University.